|  |  |   |   |                             |  |                                      |   |        |                  |      |          |               |                                  | CIO   | 0                                       | /IS                | FO | R |  |  |  |
|--|--|---|---|-----------------------------|--|--------------------------------------|---|--------|------------------|------|----------|---------------|----------------------------------|---|---|--------------------|----|---|--|--|--|
|  |  |   |   |                             |  |                                      |   |        |                  |      |          |               |                                  |   |   |                    |    |   |  |  |  |
| SUSPECT ADVERSE REACTION REPORT  |  |   |   |                             |  |                                      |   |        |                  |      |          |               |                                  |   |   |                    |    |   |  |  |  |
|  |  |   |   |                             |  |                                      | П   |        | Т                |      | Т        | $\overline{}$ | _                                | _   | <u> </u>                                | _                  | _  | Т |  |  |  |
|  |  |   |   |                             |  |                                      |   |        |                  |      |          |               |                                  |   |   |                    |    |   |  |  |  |
|  |  | 1.1   | REACTION  | INFOR                       | MATION   | I                                    |   |        |                  |      |          |               |                                  |   |   |                    |    |   |  |  |  |
| 1. PATIENT INITIALS  | 3. SEX   | 3a. WEIGHT  | _   | -6 RE                       | ACTION   | ONSI                                 | ΞT  | 8-1:   |                  |      | CK ALL   |               |                                  |   |   |                    |    |   |  |  |  |
| PRIVACY DOMINICAN REPUBLIC Day Month PRIVACY 11  |  |   |   | Male                        | Male Unk Day Month Year Unk                          |                                      |   |        |                  |      |          |               | APPROPRIATE TO ADVERSE REACTION  |   |   |                    |    |   |  |  |  |
| 7+ 13 DESCRIBE REACT Event Verbatim [LOWER L When the dose wa device] when the dose wa medication continu related to device u medication continu | s set the device a<br>s set the device a<br>led to come out a<br>se] | dministered more<br>dministered more<br>nd it came out of t | than the quar<br>than the quar<br>the patient's s | ntity set [D<br>kin. [Accid | evice deliv  | ery s                                | syste   | em iss | ue]              | ,    |          |               | NVC<br>PRO<br>HOS<br>NVC<br>DR S | ENT DI  DLVED LONGE PITALI:  DLVED SIGNIFI BILITY PACIT | OR<br>ED I<br>SAT<br>PEI<br>ICA<br>' OF | TON<br>RSIST<br>NT |    |   |  |  |  |
| (Continued on Additional Information Page)   |  |   |   |                             |  |                                      | aae)  | [      | LIFE THREATENING |      |          |               |                                  |   |   |                    |    |   |  |  |  |
|  |  | 11 0110   |   | •                           |  |                                      |   |        |                  | age, | <u> </u> | -             | 111.5                            | EAIE  | lii v                                   | 1                  |    |   |  |  |  |
| 14. SUSPECT DRUG(S) (i   | nclude generic name)   | 11. 505   | PECT DRU  | JG(S) IIV                   | FURIVIA  | 110                                  | IN  |        |                  |      | 20.      |               |                                  | CTION   |   |                    |    |   |  |  |  |
| #1 ) Genotropin Per<br>#2 ) Genotropin Per   | ,  | •   | UENT)) Soluti                                     | on for injec                | tion {Lot #  | LD75                                 |   |        |                  |      |          | ABA1<br>DRU   |                                  | FTER :  | STC                                     | PPIN               | G  |   |  |  |  |
| #1 ) 1 mg, 1x/day (at night) #1  |  |   |   | #1 ) Unkno                  | ROUTE(S) OF ADMINISTRATION<br>) Unknown<br>) Unknown |                                      |   |        |                  |      |          | YES NO NA     |                                  |   |   |                    |    |   |  |  |  |
| 17. INDICATION(S) FOR USE #1 ) Unknown #2 ) Unknown  |  |   |   |                             |  |                                      | 21. DID REACTION<br>REAPPEAR AFTER<br>REINTRODUCTION? |        |                  |      |          |               |                                  |   |   |                    |    |   |  |  |  |
| 18. THERAPY DATES(from<br>#1 ) Unknown<br>#2 ) Unknown   | #1 ) Unknown #1  |   |   |                             |  | THERAPY DURATION ) Unknown ) Unknown |   |        |                  |      |          |               | YES NO NA                        |   |   |                    |    |   |  |  |  |
| , -  |  | III. CONC   | <br>] TNATIMC                                     | ,                           |  | IST                                  | OR'   | Y      |                  |      | 1        |               |                                  |   |   |                    |    |   |  |  |  |
| 22. CONCOMITANT DRUG   |  |   |   |                             |  |                                      |   |        |                  |      |          |               |                                  |   |   |                    |    |   |  |  |  |
| 23. OTHER RELEVANT H<br>From/To Dates<br>Unknown   | STORY. (e.g. diagnosucs  | allergies, pregnancy with<br>Type of History /              |   | d, etc.)<br>Description     |  |                                      |   |        |                  |      |          |               |                                  |   |   |                    |    |   |  |  |  |
|  |  | IV. MA  | NUFACTU   | RER INI                     | ORMAT  | ION                                  | 1   |        |                  |      |          |               |                                  |   |   |                    |    |   |  |  |  |
| 24a. NAME AND ADDRES<br>Pfizer S.A.<br>Laura Arce Mora<br>Avenida Escazú, To<br>San Jose, COSTA  | rre Lexus, piso 7. I   | Escazú  |   | 26. REM                     | 1ARKS  |                                      |   |        |                  |      |          |               |                                  |   |   |                    |    |   |  |  |  |
|  | 24b. MFR CC  | NTROL NO.   |   |                             | ME AND ADDR  |                                      |   |        |                  |      |          |               |                                  |   |   |                    |    |   |  |  |  |
|  | PV20250  | 00057328  |   |                             | AND ADD  |                                      |   |        |                  |      |          |               |                                  |   |   |                    |    |   |  |  |  |
| 24c. DATE RECEIVED BY MANUFACTUREF 09-JUL-2025   |  | NAME AND ADDRESS WITHHELD.  NAME AND ADDRESS WITHHELD.      |   |                             |  |                                      |   |        |                  |      |          |               |                                  |   |   |                    |    |   |  |  |  |
| DATE OF THIS REPORT 14-JUL-2025  | 25a. REPOR   |   | WUP: 3  |                             |  |                                      |   |        |                  |      |          |               |                                  |   |   |                    |    |   |  |  |  |

## ADDITIONAL INFORMATION

## 7+13. DESCRIBE REACTION(S) continued

[Exposure via skin contact]

the case was leaking the medication [Device leakage]

the brown gummy that indicates the doses administered did not go down and continued to stay with the air [Device failure to prime]

Case Description: This is a spontaneous report received from a Nurse and a Consumer or other non HCP, Program ID: 164974.

An 11-year-old male patient received somatropin (GENOTROPIN PEN), (Lot number: LR7824, Expiration Date: Jun2027) at 1 mg 1x/day (1 mg, 1x/day (at night)), Device Lot Number: LD7551, Device Expiration Date: Jan2027. The patient's relevant medical history and concomitant medications were not reported.

The following information was reported: INCORRECT DOSE ADMINISTERED BY DEVICE (non-serious), DEVICE DELIVERY SYSTEM ISSUE (non-serious) and all described as "when the dose was set the device administered more than the quantity set"; ACCIDENTAL EXPOSURE TO PRODUCT (non-serious), EXPOSURE VIA SKIN CONTACT (non-serious) and all described as "medication continued to come out and it came out of the patient's skin."; DEVICE LEAKAGE (non-serious), described as "the case was leaking the medication"; DEVICE FAILURE (non-serious), described as "the brown gummy that indicates the doses administered did not go down and continued to stay with the air". The action taken for somatropin was unknown.

Causality for "when the dose was set the device administered more than the quantity set", "medication continued to come out and it came out of the patient's skin.", "the case was leaking the medication" and "the brown gummy that indicates the doses administered did not go down and continued to stay with the air" was determined associated to device constituent of somatropin (malfunction).

Additional information: Reporter stated that when the dose was set the device administered more than the quantity set, it did not stay at the milligrams set, so when 1 mg was set, it did not administer that. On 23May2025 nurse reported that caregiver did not take the pen to the appointment so it was not possible to correct the turns she gives. Caregiver believed it could be applying maybe more, maybe less. As of 04Jul2025, patient's caregiver reported that when administering the medication to the patient, she inserted the vial into the case, but the case was leaking the medication, she did all the steps and the respective procedure, she eliminated the air, but she saw that it still had air. Last night, when she gave the dose to the patient and it was leaking medicine through the needle, and when she inserted it into the child, the brown gummy that indicates the doses administered did not go down and continued to stay with the air. So instead of inserting everything with the needle in place (count the 10 seconds after applying it) the medication continued to come out and it came out of the patient's skin. Reporter was given a the contact of a nurse and was advised not to administer the medication until it was checked by the nurse. Upon a follow-up received on 09Jul2025, nurse stated that at first, there was an issue with the pen, but upon closer inspection, she realized the problem was due to the medication, which had a very small amount left, making it difficult for it to dispense. She tried several times and eventually identified the cause. In the end, the patient was satisfied.

Follow-up (23May2025). This is a spontaneous follow-up report received from a nurse. Updated information included: clinical course. Follow-up (27Jun2025): Follow-up attempts are completed. Batch/lot number is not provided, and it cannot be obtained.

Follow-up (04Jul2025). This is a spontaneous follow-up report received from Consumer or other non HCP, Program ID: 164974. Updated information includes: new events of "accidental exposure to product", "exposure via skin contact", device leakage and device failure to prime, additional information.

Follow-up (09Jul2025). This is a spontaneous follow-up report received from a nurse, Program ID: 164974. Updated information included: clinical course.